N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide
CAS: 1004757-96-3
Ref. 3D-EQB75796
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued |
Product Information
N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide (NAPQI) is a new drug that is being developed for the treatment of autoimmune and inflammatory diseases. It inhibits tumor necrosis factor alpha (TNFα), which is a cytokine involved in the immune response, leading to decreased inflammation. NAPQI also has the ability to inhibit the production of macrophage chemotactic protein 1 (MCP1), which is a chemokine involved in the inflammatory process. NAPQI can be used as a prodrug and modulates receptor activity by binding to TNFα, leading to reduced inflammation.